Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma

Who May Qualify: - Age ≥ 18 years old - diagnosed by tissue sample (biopsy-confirmed) gastric mucosa-associated lymphoid tissue (MALT) lymphoma; - Current infection with Helicobacter pylori (Hp): Diagnosis can be made if any of the following criteria are met: a) Positive result in at least one of the following: RUT (rapid urease test), histological staining, or bacterial culture of gastric mucosal tissue; b) Positive result in 13C or 14C-UBT (urea breath test); c) Positive result in HpSA detection. A positive result in serum Hp antibody test indicates past infection, and patients who have never been treated can be considered as having current infection. - ECOG (Eastern Cooperative Oncology Group) performance status 0-2. - Lugano staging I-II1. - Signed willing to sign a consent form form. - Evaluable lesions present. Who Should NOT Join This Trial: - Negative for Helicobacter pylori (HP); - History of other tumors, except for cured cervical cancer or basal cell carcinoma of the skin; - Patients with active HIV and syphilis infections; - Pregnant or lactating women; - Patients with severe active infections; - Patients with multiple factors affecting oral medication (such as dysphagia, nausea, vomiting, chronic diarrhea, and intestinal obstruction); - Other comorbidities or conditions that may prevent patients from completing the clinical trial. Always talk to your doctor about whether this trial is right for you.